Skip to main content
SpringerLink
Log in

More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Tuazon SA, Holmberg LA, Nadeem O et al (2021) A clinical perspective on plasma cell leukemia; current status and future directions. Blood Cancer J 11:23. https://doi.org/10.1038/s41408-021-00414-6

    Article  PubMed  PubMed Central  Google Scholar 

  2. An G, Qin X, Acharya C et al (2015) Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol 94:257. https://doi.org/10.1007/s00277-014-2211-0

    Article  PubMed  Google Scholar 

  3. Garcés J-J, Cedena M-T, Puig N et al (2022) Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol 40:3151. https://doi.org/10.1200/JCO.21.01365

    Article  CAS  PubMed  Google Scholar 

  4. Bertamini L, Oliva S, Rota-Scalabrini D et al (2022) High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol 40:3120. https://doi.org/10.1200/JCO.21.01393

    Article  CAS  PubMed  Google Scholar 

  5. Chakraborty R, Lentzsch S (2022) Circulating tumor cell burden as a component of staging in multiple myeloma: Ready for prime time? J Clin Oncol 40:3099. https://doi.org/10.1200/JCO.22.01040

    Article  PubMed  Google Scholar 

  6. Fernández de Larrea C, Kyle RA, Durie BGM et al (2013) Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27:780. https://doi.org/10.1038/leu.2012.336

    Article  CAS  PubMed  Google Scholar 

  7. Fernández de Larrea C, Kyle R, Rosiñol L et al (2021) Primary plasma cell leukemia: Consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J 11:192. https://doi.org/10.1038/s41408-021-00587-0

    Article  PubMed  PubMed Central  Google Scholar 

  8. Jelinek T, Bezdekova R, Zihala D et al (2022) More than 2% of circulating tumor plasma cells defines plasma cell leukemia–like multiple myeloma. J Clin Oncol 41:1383. https://doi.org/10.1200/JCO.22.01226

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538. https://doi.org/10.1016/S1470-2045(14)70442-5

    Article  PubMed  Google Scholar 

  10. Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised International Staging System for multiple myeloma: A report from International Myeloma Working Group. J Clin Oncol 33:2863. https://doi.org/10.1200/JCO.2015.61.2267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant # 81471165, 81670190, 81670189, 81870160, 81971108, and 82270207), the Science and Technology Development Program of the Jilin Province (Grant # 20190201042JC, 20190201163JC, and 20210509010RQ), and the Interdisciplinary Integration and Innovation Project of Jilin University. We thank all patients and participating clinicians for their support to this study.

Author information

Author notes

  1. Mengru Tian and Xinyue Liang contributed equally to this work.

Authors and Affiliations

  1. Hematology Department, Cancer Center, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China

    Mengru Tian, Xinyue Liang, Tingting Yue, Yingjie Zhang, Shanshan Yu, Yurong Yan, Zhongli Hu, Nan Zhang, Jingxuan Wang, Rui Hu, Xiaoxiao Sun, Yuanyuan Nie & Fengyan Jin

  2. Laboratory of Cancer Precision Medicine, First Hospital of Jilin University, 519 Dongminzhu Street, Changchun, 130061, Jilin, China

    Mengru Tian, Xingcheng Yi, Tingting Yue, Yingjie Zhang & Yun Dai

  3. Radiology Department, First Hospital of Jilin University, Changchun, Jilin, China

    Weiling Xu

Authors
  1. Mengru Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinyue Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weiling Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xingcheng Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tingting Yue
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yingjie Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shanshan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yurong Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Zhongli Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jingxuan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Rui Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Xiaoxiao Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yuanyuan Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yun Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Fengyan Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FJ and YD conceived the study and oversaw the project; MT, XL, WX, TY, YZ, SY, YY, ZH, NZ, JW, RH, XS, YN and FJ provided patient data; MT, YD, and FJ assembled data and performed statistical analysis; XY helped statistical analysis; YD and FJ analyzed and interpreted data; YD and FJ wrote and edited the manuscript. All authors approved the manuscript.

Corresponding authors

Correspondence to Yun Dai or Fengyan Jin.

Ethics declarations

Ethical approval

The study was approved by the Institutional Review Boards (IRBs) of the First Hospital of Jilin University (Approval # 2016–087).

Informed consent

The patient had given written informed consent to the use of clinical data according to the Declaration of Helsinki.

Conflict of interest

All authors declare that they have no conflict of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 529 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tian, M., Liang, X., Xu, W. et al. More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma. Ann Hematol 102, 2943–2945 (2023). https://doi.org/10.1007/s00277-023-05362-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05362-8

Search

Navigation